Marker Therapeutics, Inc.MRKRNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Loading chart...

Alerts

Want to monitor MRKR?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

Create free account to monitor MRKR

Key Statistics

About

tapimmune is developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. the company’s next-generation technology has been engineered to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics (i. e.

Sector

Professional, Scientific, and Technical Services

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

CEO

Peter Hoang

tapimmune.com/ →